清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

医学 临床研究阶段 CD19 内科学 耐火材料(行星科学) B细胞 慢性淋巴细胞白血病 美罗华 CD20 肿瘤科 白血病 淋巴瘤 胃肠病学 临床试验 免疫学 抗原 抗体 生物 天体生物学
作者
Claire Roddie,Eleni Tholouli,Paul Shaughnessy,Elias Jabbour,Aaron C. Logan,Katharine Hodby,Luke Mountjoy,Adrian Bloor,David Irvine,David C. Linch,Kim Orchard,William Wilson,Bilyana Popova,Juliana Dias,Giulia Agliardi,Victoria J. Spanswick,Helen L. Lowe,Marina Mitsikakou,Eftychia Charalambous,Joanna Dawes
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 2114-2114 被引量:3
标识
DOI:10.1182/blood-2023-180666
摘要

Background: Obe-cel is an autologous CD19 chimeric antigen receptor (CAR) T cell product designed to reduce toxicity and improve persistence through a fast off-rate CD19 binding domain. The clinical activity of obe-cel has been explored in adults with R/R B-ALL in a Phase I study (ALLCAR19, NCT02935257; Roddie C et al. J Clin Oncol 2021) and a Phase Ib/II study (FELIX, NCT04404660; Roddie C et al. J Clin Oncol 2023;41[16 Suppl]:7000). Additionally, obe-cel has been tested in pts with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell non-Hodgkin lymphoma (B-NHL) (ALLCAR19 extension; Roddie C et al. Blood 2022;140[1 Suppl]:7452-3). Pts from the ALLCAR19 and FELIX Phase Ib studies are in long-term follow up (≥22 mos), and the ALLCAR19 extension has been recruiting for 3 years. We report an analysis of long-term efficacy and safety data from the ALLCAR19 and FELIX Phase Ib studies, as well as data from the ALLCAR19 extension. Methods: ALLCAR19 is a multicenter, non-randomized, open-label Phase I study in pts aged ≥16 years with B-cell malignancies. ALLCAR19 initially recruited pts with R/R B-ALL but was then amended (extension study) to also include pts with R/R B-CLL and R/R B-NHL. FELIX is a global, single-arm Phase Ib/II study enrolling pts aged ≥18 years with R/R B-ALL.Study designs have been presented previously. Obe-cel was administered as a split dose in pts with B-ALL (target dose 410 × 10 6 CAR T cells) and pts with CLL (target dose 230 × 10 6 CAR T cells), and as a single infusion in pts with B-NHL (target dose 200 × 10 6 CAR T cells); the pt populations in the two studies were similar. Pts with B-ALL from the ALLCAR19 and FELIX Phase Ib studies are being followed long term for disease progression and survival. For this analysis, data in pts with B-ALL from the ALLCAR19 and FELIX Phase Ib studies were pooled. Data in pts with CLL or B-NHL are presented from the ALLCAR19 extension study. Results: Outcomes in pts with R/R B-ALL: Data in pts with B-ALL were pooled (20 pts from ALLCAR19 [data cut-off Jun 26, 2023] and 16 from FELIX Phase Ib [data cut-off Mar 16, 2023]). The median age of the pooled cohort was 41.5 (range 18 to 74) years and pts had received a median of 3 (range 2 to 6) prior lines of treatment. Twenty-nine of the 36 pts (81%) achieved complete remission (CR)/CR with incomplete hematologic recovery post obe-cel infusions, per investigator assessment. The event-free survival rate was 64% at 6 mos and 49% at 12 mos. With a median follow up of 43 (range 19 to 62) mos, 13/36 pts (36%) remain in remission (8 from ALLCAR19; 5 from FELIX Phase Ib). Among these 13 ongoing responders, 2 (15%) had consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ten of the 11 ongoing responders (91%) who did not receive allo-HSCT still had detectable CAR T cells at the last follow up. All ongoing remissions were measurable residual disease negative at last available assessment. The estimated 2-, 3- and 4-year overall survival rates were 44%, 39% and 39%, respectively. Outcomes in pts with R/R B-CLL/B-NHL: The extension phase of the ALLCAR19 study enrolled 35 pts with B-CLL or B-NHL, of which 26 (B-CLL n=5; B-NHL n=21) received obe-cel (data cut-off Jun 26, 2023). The median age of this combined cohort was 61 (range 39 to 79) years and pts had received a median of 3 (range 2 to 8) prior lines of treatment. At a median follow up of 24 mos, the overall response rate for this cohort was 92% (n=24), and 58% of responders (n=14) were alive without disease progression at last follow up. Late toxicity: Of the 11 long-term R/R B-ALL responders who had not received consolidation allo-HSCT, 10 have ongoing B-cell aplasia. Of the 14 ongoing responders in the R/R B-CLL/B-NHL cohort, 12 have ongoing B-cell aplasia (<20 B cells/µl). Of note, ongoing B-cell aplasia did not correlate with an increased risk of late serious infection. No other long-term toxicity ascribed to obe-cel was reported. Conclusions: The combined analysis of data from the ALLCAR19 and FELIX Phase Ib studies shows long-term efficacy and safety of obe-cel in pts with R/R B-ALL, with approximately one-third of pts still in remission without consolidative allo-HSCT after a median follow up of >3 years. Durable responses of >2 years were also seen in pts with R/R B-CLL and R/R B-NHL.B-cell aplasia was commonly found in long-term follow up of obe-cel recipients, but without a corresponding rise in serious late infections. Obe-cel can effect durable long-term remissions in B-cell malignancies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李煜琛完成签到 ,获得积分10
6秒前
悦耳的竺完成签到 ,获得积分10
6秒前
搜集达人的应助被冲冲冲采纳,获得10
7秒前
大力的安阳完成签到 ,获得积分10
10秒前
无花果的应助被ZLPY采纳,获得30
10秒前
17秒前
17秒前
刘亚梅完成签到 ,获得积分10
20秒前
醉熏的小凡完成签到,获得积分10
22秒前
冲冲冲发布了新的文献求助10
23秒前
apt完成签到 ,获得积分10
27秒前
33秒前
忧伤的白秋完成签到,获得积分10
35秒前
38秒前
lx完成签到 ,获得积分10
44秒前
天天快乐的应助被hilufite采纳,获得10
48秒前
nhzz2023完成签到 ,获得积分10
52秒前
和谐如彤完成签到,获得积分10
52秒前
nanjing01完成签到 ,获得积分10
53秒前
如泣草芥完成签到,获得积分10
56秒前
Jessie完成签到,获得积分10
58秒前
RZH发布了新的文献求助50
1分钟前
hy发布了新的文献求助10
1分钟前
笙歌完成签到 ,获得积分10
1分钟前
点点完成签到 ,获得积分10
1分钟前
细胞呵呵完成签到 ,获得积分10
1分钟前
cc发布了新的文献求助10
1分钟前
1分钟前
长孙烙完成签到 ,获得积分10
1分钟前
菜鸟学习完成签到 ,获得积分10
1分钟前
wayne完成签到 ,获得积分0
1分钟前
junio完成签到 ,获得积分10
1分钟前
威武的迎蓉完成签到,获得积分10
1分钟前
慎独而已完成签到,获得积分10
1分钟前
gzhy完成签到,获得积分10
1分钟前
1分钟前
科研通AI65的应助被RZH采纳,获得10
1分钟前
充电宝的应助被慎独而已采纳,获得10
1分钟前
馄饨炖饺子完成签到 ,获得积分10
1分钟前
幸世完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697